375 related articles for article (PubMed ID: 8956160)
1. Chiasmal herniation as a complication of bromocriptine therapy.
Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
[TBL] [Abstract][Full Text] [Related]
2. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
3. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
Jones SE; James RA; Hall K; Kendall-Taylor P
Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
[TBL] [Abstract][Full Text] [Related]
4. Her vision was tied down.
Dorotheo EU; Tang RA; Bahrani HM; Schiffman JS; Bhatti MT; Lewis SB
Surv Ophthalmol; 2005; 50(6):588-97. PubMed ID: 16263371
[TBL] [Abstract][Full Text] [Related]
5. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
6. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
Dhanwal DK; Sharma AK
Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
[TBL] [Abstract][Full Text] [Related]
7. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
8. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
9. Endonasal endoscopic transsphenoidal chiasmapexy using a clival cranial base cranioplasty for visual loss from massive empty sella following macroprolactinoma treatment with bromocriptine: case report.
Alvarez Berastegui GR; Raza SM; Anand VK; Schwartz TH
J Neurosurg; 2016 Apr; 124(4):1025-31. PubMed ID: 26339851
[TBL] [Abstract][Full Text] [Related]
10. Untethering of herniated left optic nerve after dopamine agonist treatment for giant prolactinoma.
Gkekas N; Primikiris P; Georgakoulias N
Acta Neurochir (Wien); 2013 Mar; 155(3):495-6. PubMed ID: 23314935
[No Abstract] [Full Text] [Related]
11. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
12. Blurred vision during airline flight reveals prolactinoma.
Bodack MI
Optometry; 2003 Mar; 74(3):159-72. PubMed ID: 12645849
[TBL] [Abstract][Full Text] [Related]
13. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic transsphenoidal treatment of a prolactinoma patient with brain and optic chiasmal herniations.
Zhang N; Guo L; Ge J; Qiu Y
J Craniofac Surg; 2014 May; 25(3):e271-2. PubMed ID: 24820730
[TBL] [Abstract][Full Text] [Related]
15. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of macroprolactinomas with delayed bromocriptine. Effectiveness of a single intramuscular injection].
García-Luna PP; Leal-Cerro A; Pereira JL; Navarro E; Trujillo F; Cortés A; Villamil F; Acosta D; Santos C; Revuelta M
Med Clin (Barc); 1990 Feb; 94(4):126-9. PubMed ID: 2325463
[TBL] [Abstract][Full Text] [Related]
17. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
18. Uncommon chiasmal lesions: demyelinating disease, vasculitis, and cobalamin deficiency.
Wilhelm H; Grodd W; Schiefer U; Zrenner E
Ger J Ophthalmol; 1993 Aug; 2(4-5):234-40. PubMed ID: 8220105
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
20. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
